申请人:——
公开号:US20020035251A1
公开(公告)日:2002-03-21
A compound of the formula
1
wherein, independently at each occurrence, v, w, and x are selected from C, N, O, and S, with H substitution as needed to fulfill open valence sites; y and z are selected from N and C, with H substitution as needed to fulfill open valence sites, with the proviso that each of w, v, x, y and z is not simultaneously C; the ring formed from v, w, x, y and z may be saturated or unsaturated; and R
1
, R
2
, R
3
and R
4
are selected from hydrogen, alkyl, aryl, alkaryl, aralkyl, heteroalkyl, and heteroaryl; wherein any adjacent two of R
1
, R
2
, R
3
and R
4
may join together to form a 5, 6 or 7-membered carbocyclic or heterocyclic ring, with the proviso that each of R
1
, R
2
, R
3
and R
4
is not simultaneously hydrogen. Pharmaceutical compositions of said compounds, and methods of use in the treatment of biological conditions including cellular hyperproliferation, are disclosed.
该化合物的化学式为1,其中,在每个出现的v、w和x处,独立地选择C、N、O和S,必要时进行H取代以满足开放价位;y和z从N和C中选择,必要时进行H取代以满足开放价位,但w、v、x、y和z中的每个都不能同时为C;由v、w、x、y和z形成的环可以是饱和的或不饱和的;以及R1、R2、R3和R4从氢、烷基、芳基、烷芳基、芳基烷基、杂环烷基和杂环芳基中选择;其中,任何相邻的两个R1、R2、R3和R4都可以结合形成5、6或7成员的碳环或杂环,但R1、R2、R3和R4中的每个都不能同时为氢。还公开了该化合物的药物组合物以及在治疗包括细胞增殖过度在内的生物状况的方法。